|

Blood Biomarkers Could Revolutionize Mesothelioma Treatment Monitoring

Blood Biomarkers Could Revolutionize Mesothelioma Treatment Monitoring

Researchers from Turkey think that biomarkers in the blood can help doctors find out if their mesothelioma patients are responding well to chemotherapy.

This new study was published in the journal Cancer Biomarkers.

Precision Medicine in Mesothelioma

Mesothelioma is a rare and aggressive cancer that is caused by asbestos. It develops in the think layer of tissue that covers many of the body’s internal organs. Most cases of mesothelioma occur in the lungs or the abdomen.

The standard treatment for mesothelioma includes a combination of surgery, chemotherapy, and radiation. The exact treatment plan is unique to each patient. Their doctor will consider the type of mesothelioma, how far it has spread, and the health of the patient.

Chemotherapy is the most “one size fits all” approach to treating mesothelioma. The standard chemotherapy treatment for mesothelioma is a combination of two drugs: Alimta (pemetrexed) and cisplatin (or carboplatin).  This is the only FDA approved chemotherapy regimen for mesothelioma.

Blood Biomarkers Could Enhance Mesothelioma Survival Rates

The researchers in this study wanted to find out if certain biomarkers could tell them how well a mesothelioma patient was responding to chemotherapy treatment. These biomarkers are special molecules found in the blood. Whether someone has a lot of biomarkers, or a few biomarkers could tell doctors important information about their health. That is what these researchers were trying to find out.

The researchers tested the blood of 64 mesothelioma patients who were treated with chemotherapy. They tested the patients’ blood before treatment and after treatment.

The blood tests showed that some of the biomarkers did change before and after treatment in patients who responded to chemotherapy. These biomarkers were called mesothelin, midkine, and HMGB1.

With more studies like this, doctors might one day be able to measure these biomarkers to find out how well their mesothelioma patients are doing with treatment. The information could help doctors to adjust treatment and improve overall survival.

Source

Bogar F, Ak G, Metintas S, Ayhanci A, Metintas M. Longitudinal monitoring of response to chemotherapy in patients with malignant pleural mesothelioma by biomarkers [published online ahead of print, 2023 Jul 17]. Cancer Biomark. 2023;10.3233/CBM-220436. doi:10.3233/CBM-220436. https://pubmed.ncbi.nlm.nih.gov/37545218/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…